IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) plus chemotherapy (chemo) +/- bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Reck, M.; Wehler, T.; Orlandi, F.; Nogami, N.; Barone, C.; Moro-Sibilot, D.; Shtivelband, M.; Gonzalez Larriba, J. L.; Rothenstein, J.; Frueh, M.; Shankar, G.; Lee, A.; Deng, Y.; Patel, H.; Kelsch, C.; Lin, W.; Socinski, M. A.

authors

Publication Date

  • October 1, 2018

webpage

published in

category

start page

  • 498

end page

  • 499

volume

  • 29